11月2日，CVS健康发布2022年第三季度业绩。财报显示，第三季度营收812亿美元，市场预期767.51亿美元，去年同期737.9亿美元；净亏损34.09亿美元，市场预期净利润22.76亿美元，去年同期净利润15.98亿美元；每股亏损2.6美元，市场预期每股收益1.71美元，去年同期每股收益1.2美元；调整后每股盈利2.09美元，市场预期为1.99美元。
第三季度业绩包含与阿片类药物相关索赔有关的52亿美元的税前费用。
将2022年调整后每股收益指引范围从8.4-8.6美元上调至8.55-8.65美元。
将2022年GAAP摊薄每股收益指引范围从7.23-7.43美元修订为3.12-3.22美元。
将2022年全年的运营现金流指引范围从125亿-135亿美元上调至135亿-145亿美元。
财报发布后，CVS健康盘前涨超5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments